Results - Announcements
Neuland Laboratories Ltd share price softened by 0.72% to Rs 19435.2 after the company's net profit tanked by 65.04% to Rs 51.63 crore, while revenue from operations nosedived 29.91% to Rs 449.66 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, gaining 5.41%. It has marginally improved by 1.84% over last one week and gained upto 1.37% in last one month while the market capitalization of Neuland Laboratories Ltd has eased by 2.90% and 9.60% in the same period respectively.
Profit before tax (PBT) of Neuland Laboratories Ltd stood at Rs 68.98 crore in Q3 FY26, tanking 46.71% year-on-year, and tumbling by 65.14% quarter-on-quarter. EBITDA came in at Rs 90 crore, nosediving by 41.42% YoY and crashing by 57.99% sequentially.
Total expenses dropped by 14.46% to Rs 380.87 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 215.79 crore, marginally falling by 5.67% YoY, while employee benefits expense was at Rs 101.76 crore, slipping by 4.39% YoY.
For the TTM ended FY26, revenue from operations soared by 36.98% to Rs 2022.99 crore, while net profit saw a strong growth of 39.94% to Rs 364.0 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 32794% to Rs 544.33 crore, and PBT witnessed a strong rise of 41.19% to Rs 488.98 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 346.68 crore in FY26, as against Rs 317.4 crore in FY25.
Neuland Laboratories Ltd jumped 13.32% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 8.41% during the same period.